CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition

On August 10, 2017, Cytori Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2017. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information disclosed under this Item 2.02 in this report, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Item 9.01Financial Statements and Exhibits

(d)Exhibits

CYTORI THERAPEUTICS, INC. Exhibit
EX-99.1 2 cytx-ex991_6.htm EX-99.1 cytx-ex991_6.htm   Exhibit 99.1                                                                                                                                                                                                                             Cytori Therapeutics contact Tiago Girao +1.858.458.0900 [email protected]         Cytori Reports Second Quarter 2017 Business and Financial Results SAN DIEGO,…
To view the full exhibit click here

About CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX)

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.